LUMETTI, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.426
AS - Asia 5.088
EU - Europa 3.751
SA - Sud America 713
Continente sconosciuto - Info sul continente non disponibili 183
AF - Africa 122
OC - Oceania 16
Totale 18.299
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.148
SG - Singapore 1.485
CN - Cina 1.273
IT - Italia 1.216
GB - Regno Unito 782
BR - Brasile 539
HK - Hong Kong 528
VN - Vietnam 504
BD - Bangladesh 376
SE - Svezia 360
DE - Germania 283
FI - Finlandia 229
FR - Francia 196
KR - Corea 182
IN - India 173
RU - Federazione Russa 171
CA - Canada 149
ID - Indonesia 120
TR - Turchia 120
UA - Ucraina 97
MX - Messico 70
JP - Giappone 62
NL - Olanda 61
AR - Argentina 58
BG - Bulgaria 55
ES - Italia 52
PL - Polonia 48
IQ - Iraq 37
ZA - Sudafrica 37
AT - Austria 33
PK - Pakistan 31
IE - Irlanda 30
MY - Malesia 25
PE - Perù 22
CO - Colombia 21
MA - Marocco 21
BE - Belgio 18
CL - Cile 18
CZ - Repubblica Ceca 17
EC - Ecuador 17
IR - Iran 17
RO - Romania 17
AE - Emirati Arabi Uniti 16
NO - Norvegia 16
CR - Costa Rica 15
SA - Arabia Saudita 15
VE - Venezuela 15
AU - Australia 14
LT - Lituania 13
TW - Taiwan 13
EG - Egitto 12
PY - Paraguay 12
TN - Tunisia 12
UZ - Uzbekistan 11
NP - Nepal 10
CH - Svizzera 9
KE - Kenya 9
AZ - Azerbaigian 8
JO - Giordania 8
GR - Grecia 7
HN - Honduras 7
IL - Israele 7
PH - Filippine 7
TH - Thailandia 7
AL - Albania 6
BH - Bahrain 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HU - Ungheria 6
KZ - Kazakistan 6
BZ - Belize 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
AO - Angola 4
BB - Barbados 4
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
DK - Danimarca 4
DZ - Algeria 4
EU - Europa 4
GE - Georgia 4
JM - Giamaica 4
KG - Kirghizistan 4
KH - Cambogia 4
RS - Serbia 4
UY - Uruguay 4
AM - Armenia 3
LB - Libano 3
NG - Nigeria 3
OM - Oman 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
GT - Guatemala 2
HR - Croazia 2
KW - Kuwait 2
Totale 18.085
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.001
Singapore 937
Ashburn 880
San Jose 626
Hong Kong 521
Fairfield 446
Southend 415
Chandler 414
Council Bluffs 407
Hefei 407
Woodbridge 252
London 200
Houston 196
Beijing 192
Nyköping 190
Ann Arbor 180
New York 174
Los Angeles 170
Seoul 170
Helsinki 166
Seattle 164
Wilmington 153
Jacksonville 150
Hanoi 147
Ho Chi Minh City 143
Cambridge 135
The Dalles 129
Modena 122
Dearborn 109
Milan 109
Chicago 99
San Diego 90
Jakarta 89
Bologna 84
Lauterbourg 73
Buffalo 68
Princeton 59
Shanghai 58
Rome 56
Izmir 54
Sofia 54
Atlanta 52
São Paulo 52
Parma 49
Moscow 48
Dallas 47
Munich 45
Frankfurt am Main 44
Orem 40
Bremen 39
Tokyo 39
Warsaw 37
Columbus 36
Naples 36
Montreal 35
Salt Lake City 34
Boardman 32
Toronto 32
Denver 30
Florence 29
Lappeenranta 28
Delhi 27
Eugene 25
Turin 24
Guangzhou 23
Kent 23
Paris 23
Stockholm 23
Da Nang 22
Haiphong 22
New Delhi 22
Reggio Emilia 22
Valencia 22
Amsterdam 21
Johannesburg 21
Mexico City 21
Chennai 20
Dublin 20
Mumbai 20
Redondo Beach 20
Phoenix 19
Redwood City 19
Brooklyn 17
Charlotte 17
Ottawa 17
Lima 16
Rio de Janeiro 16
San Francisco 16
Turku 16
Brussels 15
Manchester 15
Vancouver 15
Baghdad 13
Ovada 13
Poplar 13
Querétaro 13
Ankara 12
Boston 12
Elk Grove Village 12
Hillsboro 12
Totale 11.592
Salva come PNG Salva come JPEG
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 435
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 375
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 350
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 349
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 343
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 331
Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature 316
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 312
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 308
APPLICATION OF CRITERIA FOR THE DIAGNOSIS OF “CLINICAL OSTEOPOROSIS ” IN A POPULATION OF POSTMENOPAUSAL WOMEN FROM EMILIA-ROMAGNA REGION 304
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 285
Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study 284
COMPLEMENT DEPLETION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB: A MARKER OF CLINICAL EFFICACY? 277
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 275
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 273
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 267
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 265
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature 262
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 262
Scleroderma Digital Ulcers Complicated by Infection with Fecal Pathogens. 260
Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis 258
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 256
A SELF-ADMINISTERED QUESTIONNAIRE MAY ALLOW GENERAL PRACTITIONERS TO PERFORM A RAPID SCREENING TO IDENTIFY PATIENTS AT RISK FOR FRAGILITY FRACTURES AND TO ADDRESS THEM TO BONE METABOLISM SPECIALIZED CLINICAL CENTERS 254
RETENTION RATE OF ADALIMUMAB AND ABP 501 IN THE TREATMENT OF A LARGE COHORT OF PATIENTS WITH INFLAMMATORY ARTHRITIS: A REAL LIFE RETROSPECTIVE ANALYSIS 251
Osteomyelitis complicating scleroderma digital ulcers. 248
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 243
Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature 241
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 235
Baseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study 226
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 226
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 226
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 225
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 223
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 221
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07) 217
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 216
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 214
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 214
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 212
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 212
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 208
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 208
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 205
Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis 205
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 205
Predictive Value of DLCO Reduction in Scleroderma Patients Without Cardio-Pulmonary Involvement at Baseline 202
Treatment with Rituximab in Systemic Sclerosis Patients: Our Experience in a Pilot Clinical Trial 194
Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study 192
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 190
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 187
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 184
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 181
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 179
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 177
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 176
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 174
Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study 171
PSYCHIATRIC DISORDERS IN RHEUMATOLOGY: EVALUATION OF A SCREENING PROTOCOL IN 100 HOSPITALIZED PATIENTS 170
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 167
CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY 164
KIENBOCK DISEASE IN A PATIENT WITH SSc: A CASE REPORT 162
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 159
CONFRONTO TRA STRATEGIE DI TERAPIA AVANZATA DI 2° E 3° LINEA NELLA ARTRITE PSORIASICA: RISULTATI PRELIMINARI DALLO STUDIO OSSERVAZIONE RETROSPETTIVO BIRRA 157
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 156
Cycling versus swapping strategieswith TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice 153
POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS 150
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 146
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 142
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 142
DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA 137
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 136
Infections of scleroderma digital ulcers: A single center cohort retrospective study 127
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup— AMulticenter Study 125
Influence of safety warnings on the prescribing attitude of JAK 2inhibitors for rheumatoid arthritis in Italy 125
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 120
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study 114
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 114
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis 114
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 106
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 104
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study 101
FRI0651 Quantitative chest ct predicts 8-years-mortality and comorbidity in systemic sclerosis 101
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 97
Elderly-onset systemic sclerosis defines a distinct clinical subset: analysis from the SPRING registry of the Italian Society for Rheumatology 95
Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study 95
Comparative effectiveness of cycling versus swapping to UL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real- world multicenter study 75
The clinical profile of systemic sclerosis without a ‘scleroderma pattern’ at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology 73
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort 65
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al 62
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry. 54
Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR) 52
Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry 52
Guselkumab effectiveness in real-world settings: Observations from an Italian multicentre study 44
Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis 38
Exploring Disease-Specific Risk Factors for Vertebral Fractures in Systemic Sclerosis: Insights from the ScleroRER Study Group 32
Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) 31
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study 20
Clinical and serological features of triple autoantibody-­ negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology 18
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study 15
Totale 18.299
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.084 0 0 86 100 47 88 42 91 150 95 243 142
2022/20231.261 157 147 89 114 127 160 51 119 177 19 51 50
2023/2024970 27 61 47 143 196 55 84 98 23 33 74 129
2024/20253.728 121 52 64 233 740 599 313 198 428 145 343 492
2025/20267.573 482 272 520 909 947 500 898 386 701 762 709 487
2026/2027968 321 627 20 0 0 0 0 0 0 0 0 0
Totale 18.299